Literature DB >> 15576456

Structural and functional characteristics of the Val44Met insulin-like growth factor I missense mutation: correlation with effects on growth and development.

Adam Denley1, Chunxiao C Wang, Kerrie A McNeil, Marie J E Walenkamp, Hermine van Duyvenvoorde, Jan M Wit, John C Wallace, Raymond S Norton, Marcel Karperien, Briony E Forbes.   

Abstract

We have previously described the phenotype resulting from a missense mutation in the IGF-I gene, which leads to expression of IGF-I with a methionine instead of a valine at position 44 (Val44Met IGF-I). This mutation caused severe growth and mental retardation as well as deafness evident at birth and growth retardation in childhood, but is relatively well tolerated in adulthood. We have conducted a biochemical and structural analysis of Val44Met IGF-I to provide a molecular basis for the phenotype observed. Val44Met IGF-I exhibits a 90-fold decrease in type 1 IGF receptor (IGF-1R) binding compared with wild-type human IGF-I and only poorly stimulates autophosphorylation of the IGF-1R. The ability of Val44Met IGF-I to signal via the extracellular signal-regulated kinase 1/2 and Akt/protein kinase B pathways and to stimulate DNA synthesis is correspondingly poorer. Binding or activation of both insulin receptor isoforms is not detectable even at micromolar concentrations. However, Val44Met IGF-I binds IGF-binding protein-2 (IGFBP-2), IGFBP-3, and IGFBP-6 with equal affinity to IGF-I, suggesting the maintenance of overall structure, particularly in the IGFBP binding domain. Structural analysis by nuclear magnetic resonance confirms retention of near-native structure with only local side-chain disruptions despite the significant loss of function. To our knowledge, our results provide the first structural study of a naturally occurring mutant human IGF-I associated with growth and developmental abnormalities and identifies Val44 as an essential residue involved in the IGF-IGF-1R interaction.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15576456     DOI: 10.1210/me.2004-0409

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  17 in total

Review 1.  Neurodevelopmental effects of insulin-like growth factor signaling.

Authors:  John O'Kusky; Ping Ye
Journal:  Front Neuroendocrinol       Date:  2012-06-16       Impact factor: 8.606

2.  Viral expression of insulin-like growth factor I E-peptides increases skeletal muscle mass but at the expense of strength.

Authors:  Becky K Brisson; Janelle Spinazzola; SooHyun Park; Elisabeth R Barton
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-02-25       Impact factor: 4.310

3.  Design of an insulin analog with enhanced receptor binding selectivity: rationale, structure, and therapeutic implications.

Authors:  Ming Zhao; Zhu-li Wan; Linda Whittaker; Bin Xu; Nelson B Phillips; Panayotis G Katsoyannis; Faramarz Ismail-Beigi; Jonathan Whittaker; Michael A Weiss
Journal:  J Biol Chem       Date:  2009-09-22       Impact factor: 5.157

Review 4.  IGF-1 in retinopathy of prematurity, a CNS neurovascular disease.

Authors:  Raffael Liegl; Chatarina Löfqvist; Ann Hellström; Lois E H Smith
Journal:  Early Hum Dev       Date:  2016-09-17       Impact factor: 2.079

5.  A novel approach to identify two distinct receptor binding surfaces of insulin-like growth factor II.

Authors:  Clair L Alvino; Kerrie A McNeil; Shee Chee Ong; Carlie Delaine; Grant W Booker; John C Wallace; Jonathan Whittaker; Briony E Forbes
Journal:  J Biol Chem       Date:  2009-01-12       Impact factor: 5.157

6.  The pro-forms of insulin-like growth factor I (IGF-I) are predominant in skeletal muscle and alter IGF-I receptor activation.

Authors:  Julia Durzyńska; Anastassios Philippou; Becky K Brisson; Michelle Nguyen-McCarty; Elisabeth R Barton
Journal:  Endocrinology       Date:  2013-02-13       Impact factor: 4.736

7.  Alanine scanning of a putative receptor binding surface of insulin-like growth factor-I.

Authors:  Lisbeth Gauguin; Carlie Delaine; Clair L Alvino; Kerrie A McNeil; John C Wallace; Briony E Forbes; Pierre De Meyts
Journal:  J Biol Chem       Date:  2008-05-23       Impact factor: 5.157

Review 8.  IGF2: epigenetic regulation and role in development and disease.

Authors:  Wendy Chao; Patricia A D'Amore
Journal:  Cytokine Growth Factor Rev       Date:  2008-03-04       Impact factor: 7.638

9.  New Modulators for IGF-I Activity within IGF-I Processing Products.

Authors:  Becky K Brisson; Elisabeth R Barton
Journal:  Front Endocrinol (Lausanne)       Date:  2013-03-27       Impact factor: 5.555

Review 10.  Genetic causes of growth hormone insensitivity beyond GHR.

Authors:  Vivian Hwa; Masanobu Fujimoto; Gaohui Zhu; Wen Gao; Corinne Foley; Meenasri Kumbaji; Ron G Rosenfeld
Journal:  Rev Endocr Metab Disord       Date:  2020-10-08       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.